An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Repare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Repare Therapeutics Inc. (NASDAQ: RPTX) announced participation in two virtual investor conferences in February 2022. The Guggenheim Oncology Conference is scheduled for February 10, 2022 at 2:00 p.m. ET, while the 11th Annual SVB Leerink Global Healthcare Conference will take place on February 18, 2022 at 3:00 p.m. ET. Live webcasts for both presentations will be available on the Company's website, with archiving for 90 days. Repare specializes in precision oncology, utilizing its SNIPRx® platform for targeted cancer therapies.
Positive
None.
Negative
None.
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will participate in two virtual investor conferences in February. Details are as follows:
Guggenheim Oncology Conference Date: Thursday, February 10, 2022 Time: 2:00 p.m. Eastern Time
11th Annual SVB Leerink Global Healthcare Conference Date: Friday, February 18, 2022 Time: 3:00 p.m. Eastern Time
A live webcast of the Guggenheim Oncology Conference fireside chat will be available starting Thursday, February 10, 2022 at 2:00 p.m. Eastern Time in the Investor section of the Company’s website at https://ir.reparerx.com/news-and-events/events. A replay of the webcast will be archived on the Company’s website for 90 days.
A live webcast of the 11th Annual SVB Leerink Global Healthcare Conference presentation will be available on Friday, February 18, 2022 at 3:00 p.m. Eastern Time in the Investor section of the Company’s website at https://ir.reparerx.com/news-and-events/events. A replay of the webcast will be archived on the Company’s website for 90 days.
About Repare Therapeutics, Inc.
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor currently in Phase 1/2 clinical development, its second clinical candidate, RP-6306, a PKMYT1 inhibitor currently in Phase 1 clinical development, a Polθ inhibitor program, as well as eight other early-stage, pre-clinical programs. For more information, please visit reparerx.com.
SNIPRx® is a registered trademark of Repare Therapeutics Inc.
What dates will Repare Therapeutics participate in investor conferences?
Repare Therapeutics will participate in the Guggenheim Oncology Conference on February 10, 2022, and the SVB Leerink Global Healthcare Conference on February 18, 2022.
What is the significance of the SNIPRx® platform for Repare Therapeutics?
The SNIPRx® platform enables Repare Therapeutics to discover and develop targeted cancer therapies focusing on genomic instability.
Where can I watch the live webcasts for the Repare Therapeutics conferences?
Live webcasts for the conferences can be watched on Repare Therapeutics' website in the Investor section.
How long will the webcasts of Repare Therapeutics' presentations be available?
The webcasts will be archived on the Company's website for 90 days.
What are the lead product candidates for Repare Therapeutics?
Repare Therapeutics' lead product candidates include RP-3500, an ATR inhibitor, and RP-6306, a PKMYT1 inhibitor.
